DrugBiological
Lutikizumab clinical trials
Also written ABT-981.
Keep track of what changes. Save the lutikizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2021 | 1 |
| 2024 | 5 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Risankizumab (2) · Adalimumab (1) · Ravagalimab (1) · Trosunilimab (1) · ABBV-8736 (1)
Studies
Open first, then newest update. How each study uses lutikizumab is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisRecruitingPhase 2AbbVieNCT06972446Written as Lutikizumab
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingPhase 2AbbVieNCT06548542Written as Lutikizumab
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisRecruitingPhase 2AbbVieNCT06865105Written as Lutikizumab
- A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of LutikizumabRecruitingPhase 2AbbVieNCT06524635Written as Lutikizumab
- A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingPhase 3AbbVieNCT06468228Written as Lutikizumab
- A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic DermatitisActive, not recruitingPhase 2AbbVieNCT06718101Written as Lutikizumab
- A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic TherapyActive, not recruitingPhase 2AbbVieNCT05139602Written as Lutikizumab
- A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative ColitisActive, not recruitingPhase 2AbbVieNCT06257875Written as Lutikizumab
- A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee OsteoarthritisCompletedPhase 2AbbVieNCT02087904Written as ABT-981
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the KneeCompletedPhase 1AbbVie (prior sponsor, Abbott)NCT01668511Written as ABT-981
- A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand OsteoarthritisCompletedPhase 2AbbVieNCT02384538Written as ABT-981
Codes
What other systems call lutikizumab · ClinicalTrials.gg INT001218
- MeSH (NLM) C000655035lutikizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 15FAZ725S0LUTIKIZUMABConfirmed FDA, NLM
- NCI Thesaurus C166465LutikizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000655035 | lutikizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 15FAZ725S0 | LUTIKIZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C166465 | Lutikizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.